Dual inhibition with curzerene (a GSTA1 inhibitor) and β-catenin-IN-2 (a CTNNB1 inhibitor) synergistically reinstates ferroptotic sensitivity, suppressing tumor growth in cell lines, patient-derived organoids, and xenograft models. The gene discussed is CTNNB1; the disease is neoplasm.